Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 11—November 2004
Research

Evaluating Human Papillomavirus Vaccination Programs

Al V. Taira*, Christopher P. Neukermans†, and Gillian D. Sanders†‡Comments to Author 
Author affiliations: *Stanford School of Medicine, Stanford, California, USA; †Stanford University, Stanford, California, USA; ‡Duke University, Durham, North Carolina, USA

Main Article

Figure 2

A) Vaccine penetration scenario. Relationship between percentage of the population receiving the vaccine and the number of lifetime cervical cancer cases. The solid line represents a female-only vaccination strategy. The dashed line represents a strategy of vaccinating both sexes. The arrow indicates the base-case scenario of a female-only strategy with 70% penetration. B) Vaccine penetration scenario. Relationship between percentage of the population receiving the vaccine and program cost-effec

Figure 2. . A) Vaccine penetration scenario. Relationship between percentage of the population receiving the vaccine and the number of lifetime cervical cancer cases. The solid line represents a female-only vaccination strategy. The dashed line represents a strategy of vaccinating both sexes. The arrow indicates the base-case scenario of a female-only strategy with 70% penetration. B) Vaccine penetration scenario. Relationship between percentage of the population receiving the vaccine and program cost-effectiveness. The solid line represents the cost-effectiveness ($/quality-adjusted life-year [QALY]) of a female-only vaccination program compared to current practice. The dashed line represents the incremental cost-effectiveness of including male participants in a vaccine program compared to a female-only strategy. The arrow indicates the base-case scenario of a female-only program with 70% penetration. C) Vaccine efficacy scenario. Relationship between vaccine efficacy and the number of cohort lifetime cervical cancer cases. The solid line represents a female-only vaccination strategy. The dashed line represents a strategy of vaccinating both sexes. The arrow indicates the base-case scenario of a female-only strategy assuming 90% vaccine efficacy. D) Vaccine efficacy scenario. Relationship between vaccine efficacy and program cost-effectiveness. The solid line represents the cost-effectiveness ($/quality-adjusted life-year [QALY]) of a female-only vaccination program compared to current practice. The dashed line represents the incremental cost-effectiveness of including male participants in a vaccine program compared to a female-only strategy. The arrow indicates the base-case scenario of a female-only program at 90% vaccine efficacy.

Main Article

Page created: April 17, 2012
Page updated: April 17, 2012
Page reviewed: April 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external